Caangay, Teresita .
HRN: 22-95-88 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/28/2023
REMDESIVIR 100MG (VIAL)
04/28/2023
05/07/2023
IV
200mg Now, Then 100mg OD
OD
COVID-19
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes